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Context: Several noninvasive tests have been developed for diagnosing bladder outlet
obstruction (BOO) in men to avoid the burden and morbidity associated with invasive
urodynamics. The diagnostic accuracy of these tests, however, remains uncertain.
Objective: To systematically review available evidence regarding the diagnostic accu-
racy of noninvasive tests in diagnosing BOO in men with lower urinary tract symptoms
(LUTS) using a pressure-ﬂow study as the reference standard.
Evidence acquisition: The EMBASE, MEDLINE, Cochrane Database of Systematic
Reviews, Cochrane Central, Google Scholar, and WHO International Clinical Trials
Registry Platform Search Portal databases were searched up to May 18, 2016. All studies
reporting diagnostic accuracy for noninvasive tests for BOO or detrusor underactivity in
men with LUTS compared to pressure-ﬂow studies were included. Two reviewers
independently screened all articles, searched the reference lists of retrieved articles,
and performed the data extraction. The quality of evidence and risk of biaswere assessed
using the QUADAS-2 tool.
Evidence synthesis: The search yielded 2774 potentially relevant reports. After screen-
ing titles and abstracts, 53 reports were retrieved for full-text screening, of which 42
4444 patients) were eligible. Overall, the results were predomi-
ings from nonrandomised experimental studies and, within the
designs, the quality of evidence was typically moderate across thenantly based on ﬁnd
limits of such study(recruiting a total ofliterature. Differences in noninvasive test threshold values and variations in the uro-
of BOO between studies limited the comparability of the data.dynamic deﬁnitionPlease visit www.eu-acme.org/
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Detrusor wall thickness (median sensitivity 82%, speciﬁcity 92%), near-infrared spectros-
copy (median sensitivity 85%, speciﬁcity 87%), and the penile cuff test (median sensitivity
88%, speciﬁcity 75%) were all found to have high sensitivity and speciﬁcity in diagnosing
BOO. Uroﬂowmetry with a maximum ﬂow rate of <10 ml/s was reported to have lower
median sensitivity and speciﬁcity of 68% and 70%, respectively. Intravesical prostatic
protrusion of >10 mm was reported to have similar diagnostic accuracy, with median
sensitivity of 68% and speciﬁcity of 75%.
Conclusions: According to the literature, a number of noninvasive tests have high sensi-
tivity and speciﬁcity in diagnosing BOO in men. However, although the majority of studies
have a low overall risk of bias, the available evidence is limited by heterogeneity. While
several tests have shown promising results regarding noninvasive assessment of BOO,
invasive urodynamics remain the gold standard.
Patient summary: Urodynamics is an accurate but potentially uncomfortable test for
patients in diagnosing bladder problems such as obstruction. We performed a thorough
and comprehensive review of the literature to determine if there were less uncomfortable
but equally effective alternatives to urodynamics for diagnosing bladder problems. We
found that some simple tests appear to be promising, although they are not as accurate.
Further research is needed before these tests are routinely used in place of urodynamics.
# 2016 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Lower urinary tract symptoms (LUTS) are prevalent and
bothersome in men and women of all ages. Determining
whether these symptoms are due to bladder outflow
obstruction (BOO) is important in determining the optimal
management [1]. Indeed, the success rate for surgical
procedures such as transurethral resection of the prostate is
presumed to be superior in patients with urodynamically
documented BOO. However, it is not possible to reliably
diagnose BOO on the basis of clinical symptoms alone, and
the gold standard for diagnosis is urodynamic assessment
via a pressure-flow study. However, this is an invasive test
with risks of bothersome urinary symptoms, haematuria,
and urinary tract infection. Furthermore, it can be
unpleasant, with considerable rates of anxiety and embar-
rassment [2]. It also requires dedicated equipment and
specific expertise, and is expensive. Consequently, a
number of noninvasive tests have been described to replace
the pressure-flow study in diagnosing BOO in men with
LUTS. The objective of this systematic review (SR) is to
determine the diagnostic accuracy of noninvasive tests in
diagnosing BOO in men with LUTS with reference to the
gold standard of invasive urodynamics.
2. Evidence acquisition
We used standard methods recommended by the Cochrane
Methods Group for the Systematic Review of Screening and
Diagnostic Tests [3], Preferred Reporting Items for System-
atic Reviews (PRISMA), and Standards for Reporting
Diagnostic Accuracy Studies (STARD) [4]. The study protocol
was published on PROSPERO (CRD42015019412).
2.1. Search strategy
An experienced research librarian collaborated in planning
the search strategy. The EMBASE, MEDLINE, Cochrane
Database of Systematic Reviews, Cochrane Central
(Cochrane HTA, DARE, HEED), Google Scholar, and WHOinternational Clinical Trials Registry Platform Search Portal
databases were searched up to May 18, 2016. Only English
language articles were included. The detailed search
strategy is described in the Supplementary material.
Additional sources for articles included the reference lists
of the studies included and clinical content experts (EAU
Male LUTS Guideline Panel). Two reviewers (SM and RU)
screened all abstracts and full-text articles independently.
Disagreement was resolved by discussion; if no agreement
was reached, a third independent party acted as an arbiter
(AKN).
2.2. Types of study design included
All types of studies (including at least 10 participants)
assessing the diagnostic accuracy of noninvasive tests
using invasive urodynamics as a reference standard were
eligible.
2.3. Types of participant included
Eligible study populations recruited adult men (18 yr)
with LUTS (as defined by the study authors). Studies in
which the proportion of men with either neurologic disease
or urethral stricture was >10% were excluded.
2.4. Types of intervention included
The following noninvasive tests (ie, index tests) were
eligible for inclusion. A detailed description of each index
test is included in the Supplementary material.(1) Prostate volume/height(2) Intravesical prostate protrusion (IPP)(3) Detrusor/bladder wall thickness measured on transab-
dominal ultrasound (DWT/BWT)(4) Ultrasound-estimated bladder weight (UEBW)(5) Doppler ultrasound(6) Near-infrared spectroscopy (NIRS)(7) Uroflowmetry
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 3 9 1 – 4 0 2 393(8) Penile cuff test (PCT)(9) External condom catheter method2.5. Outcome measures
The primary outcome measures for diagnostic accuracy in
predicting BOO were sensitivity, specificity, positive pre-
dictive value (PPV), and negative predictive value (NPV).
Secondary outcome measures included test reliability and
reproducibility, adverse events, patient satisfaction, and
cost effectiveness as defined by the trial authors, if reported.
2.6. Assessment of risk of bias
The risk of bias (RoB) in the studies included was assessed
using the QUADAS-2 tool [5]. The tool consists of four
domains (patient selection, index test, reference standard,
and flow of patients through the study) and timing of the
index test and reference standard. RoB was assessed for
each domain, and the first three domainswere also assessed
for concerns regarding applicability.
A list of the most important potential confounders for
outcomes was developed a priori with clinical content
experts (EAU Non-neurogenic Male LUTS Guideline Panel).
The confounder assessment consisted of whether each
prognostic confounder was considered and whether,
if necessary, the confounder was controlled for in the
analysis. The potential confounding factors assessed were:
(1) whether indices for a pressure-flow study were deter-
mined automatically or manually; (2) whether the quality of
the urodynamic study adhered to contemporaneous quality
standards (International Continence Society [ICS] standards
for studies from 2002 onwards; for studies before 2002,
judgment was made by the reviewer and panel member).
2.7. Data analysis
Owing to the expected heterogeneity in the definitions,
thresholds, and technical variations of the index tests, a
qualitative (ie, narrative) synthesis of all included studies
was planned. For studies with multiple publications, only
the most up-to-date or complete data for each outcome
were analysed.
Subgroup analyses were planned for the following
groups if data were available: high versus low prevalence
of benign prostatic enlargement (BPE); men with a high
prevalence of detrusor underactivity; men with storage
versus voiding LUTS; severity of LUTS; men with previous
prostate surgery; men treated with medical therapy for
storage and/or voiding LUTS; and risk factors for BPE
(prostate-specific antigen, prostate volume, post-void
residual urine).
For each study, the elements of diagnostic accuracy were
determined using a two-by-two contingency table consist-
ing of true positive (TP), false positive (FP), false negative
(FN), and true negative (TN) rates based on data reported by
the study authors. If there was discrepancy between the
observed data (TP, FP, FN, and TN) and derived data
(sensitivity, specificity, PPV, and NPV), the observed datatook priority, and diagnostic accuracy elements were
calculated from the observed data as reported by the
authors. In addition, descriptive statistics includingmedian,
interquartile range, and range were provided for all
diagnostic accuracy elements for each type of index test
considered as a whole to provide a summary measure
across studies. Sensitivity analysis was planned for each
type of index test using the most commonly used threshold
values relevant to each test only.
3. Evidence synthesis
3.1. Quantity of evidence identified
The study selection process is outlined in Fig. 1. A total of
42 studies were eligible for inclusion: 41 nonrandomised
experimental studies and one retrospective comparative
study [6–47].
3.2. Characteristics of the studies included
The baseline characteristics for all 42 studies included are
shown in Table 1. A total of 4444 patients were recruited.
3.3. RoB assessment
A summary of the methodological quality and RoB
assessments is shown in Figure 2. The majority of studies
had low RoB in terms of applicability, with most studies
including men representative of those who would be
expected to undergo this test in routine practice. The study
by Botkor-Rasmussen et al [12] included a larger proportion
of asymptomatic or minimally symptomaticmen compared
to the other studies, and Sullivan et al [44] included some
normal volunteers, which could therefore affect the
applicability of the accuracy results obtained. Hirayama
et al [21] included only men with a small prostate (<20 ml)
which is not a representative sample of those who would
receive the test in clinical practice, and Kuo et al [27] used a
definition of BOO on urodynamics (detrusor pressure at
peak flow rate>50 cmH2O) that is not widely accepted and
therefore may affect the accuracy of the results.
The principal source of bias across studieswas related to
reporting of the reference standard. Although the ICS
nomogram is now widely accepted to define BOO on
voiding cystometry, a number of studies used different
definitions of BOO which may affect the diagnostic
accuracy results obtained. Furthermore, some studies
classified both equivocal and non-obstructed patients into
the same non-obstructed group which may introduce an
element of bias into the overall results [6]. In addition,
blinding to the index test and reference standardwas either
not clearly discussed or was not performed in a number of
studies, again accounting for an unclear or high RoB in data
interpretation across studies. In the studies assessing NIRS,
the index test and reference standard had to be undertaken
simultaneously and so this introduces a RoBwith the same
investigator analysing the results of both tests at the same
time.
[(Fig._1)TD$FIG]
Fig. 1 – Preferred Reporting Items for Systematic Reviews flow diagram for selection of articles for the systematic review.
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across most studies, although there was significant
heterogeneity of definitions of thresholds, index tests and
reference tests.
3.4. Narrative synthesis of the results
3.4.1. Diagnostic accuracy results
The individual results for each study, organised according to
the index test being assessed, are shown in Table 2. The
overall results for each type of index test considered areTable 1 – Baseline characteristics of the studies included
Study Pts (n) Study
design
Index test
Abdel-Aal 2011 [6] 85 NRE DWT
IPP
Combination IPP + DWT
Aganovic 2004 [7] 102 NRE Uroﬂowmetryavailable in Tables 3 and 4. It was not possible to perform
subgroup analyses because of a lack of data.
3.4.1.1. PCT. Seven studies investigated the diagnostic accu-
racy of PCT. Overall, the diagnostic accuracy was high, with
median sensitivity of 88% and specificity of 70%. There was
low RoB across most studies, but significant heterogeneity
in the threshold values used to diagnose BOO, with three
studies using the nomogram developed by Griffiths et al
[11,18,22], two using different nomograms [32,42], and two
using a penile urethral compression-release index of eitherThreshold value Blinding BOO deﬁnition for
reference standard
2 mm Yes BOOI >40
8 mm
8 mm + 2 mm
10 ml/s NR LPURR >2 or >3
LPURR>2 + URA >29
Qmax <15 and PdetQmax >50
Table 1 (Continued )
Study Pts (n) Study
design
Index test Threshold value Blinding BOO deﬁnition for
reference standard
Aganovic 2012 [8] 111 NRE IPP 10 mm NR BOOI >40
BWT 5 mm
Aganovic 2012 [9] 112 NRE IPP 12 mm NR BOOI >40
BOON 27.2 BOOI >40
BOON 27.2 URA >29
Combination IPP + BOON 10 mm, 30 BOOI >40
BOON2 47.4 and 50 URA >29
Belenky 2003 [10] 29 NRE Doppler ultrasound RI T > 0.05 Yes BOOI >40
Bianchi 2014 [11] 48 NRE PCT Grifﬁths nomogram No BOOI >40
Botkor-Rasmussen 1999 [12] 29 NRE Uroﬂowmetry 10 ml/s No BOOI >40
Chia 2003 [13] 200 NRE Uroﬂowmetry 10 ml/s Yes BOOI >40
IPP 10 mm




Dicuio 2005 [15] 25 NRE IPP 10 mm No DAMPF score
El Saied 2013 [16] 50 NRE DWT 2 mm Yes BOOI >40
Uroﬂowmetry 10 ml/s
Prostate volume 25 ml
Franco 2010 [17] 100 NRE IPP 12 mm Yes BOOI >40
DWT 6 mm
Prostate height 40 mm
Prostate volume 38 ml
Grifﬁths 2005 [18] 144 NRE PCT Grifﬁths nomogram No BOOI >40
Uroﬂowmetry 10 ml/s
Han 2011 [19] 193 NRE Corrected UEBW
(UEBW/BSA)
27.86 g NR BOOI >40
Harding 2004 [20] 101 NRE PCT PCR index 160% Yes BOOI >40
Uroﬂowmetry 10 ml/s
Hirayama 2002 [21] 36 NRE Uroﬂowmetry 10 ml/s NR BOOI >40
Kazemeyni 2015 [22] 51 NRE PCT Grifﬁths nomogram NR BOOI >40
Keqin 2007 [23] 206 RS IPP 8.5 NR BOOI >40
Kessler 2006 [24] 102 NRE DWT 1.5, 2, 2.5, 2.9 mm No BOOI >40
Kojima 1997 [25] 65 NRE UEBW 35 g No BOOI >40
Ku 2009 [26] 212 NRE Uroﬂowmetry 10, 12, 15 ml/s No BOOI >40
Residual fraction 10%, 20%, 30%
Kuo 1999 [27] 324 NRE Uroﬂowmetry 10 ml/s No PdetQmax >50
Lim 2006 [28] 95 NRE IPP 10 mm NR BOOI >40
Prostate volume 40 ml
MacNab 2008 [29] 55 NRE NIRS NIRS algorithm No Not deﬁned
Madersbacher 1997 [30] 253 NRE Uroﬂowmetry 5 ml/s No LPURR >2
Manieri 1998 [31] 170 NRE BWT 5 mm Yes URA >29
Matulewicz 2015 [32] 19 NRE PCT Modiﬁed ICS nomogram No NR
Oelke 2002 [34] 70 NRE DWT 2 mm NR CHESS
Uroﬂowmetry 15 ml/s
Oelke 2007 [33] 160 NRE DWT 2 mm Yes BOOI >40
Uroﬂowmetry 10 and 15 ml/s
Ozawa 2000 [35] 22 NRE Doppler ultrasound VR >1.6 NR BOOI >40
Pascual 2011 [36] 39 NRE MLL 10.5 mm No BOOI >40
Pel 2002 [37] 56 NRE External condom catheter Qmax/Pext max No BOOI >40
Poulsen 1994 [38] 153 NRE Uroﬂowmetry 10 ml/s No BOOI >40
Reis 2008 [39] 42 NRE IPP 10 and 5 mm Yes BOOI >40
Reynard 1996 [40] 148 NRE Uroﬂowmetry 10 ml/s 1st void No BOOI >40
Uroﬂowmetry – multiple 10 ml/s 4th void
Reynard 1998 [41] 897 NRE Uroﬂowmetry 10 ml/s No Shafer nomogram
Salinas 2003 [42] 93 NRE PCT Nomogram described Yes BOOI >40
Stothers 2010 [43] 64 NRE NIRS CART model No BOOI >40
Sullivan 2000 [44] 90 NRE Penile compression release PCR 100% NR VPG >5 cm H2O
Watanabe 2002 [45] 51 NRE Prostate volume and H:W 30 ml and 0.8 No LPURR 3
Yurt 2012 [46] 53 NRE NIRS NIRS algorithm No BOOI >40
Zhang 2013 [47] 87 NRE NIRS NIRS algorithm Yes BOOI >40
Uroﬂowmetry + PVR 10 ml/s and 100 ml
BOOI = bladder outﬂow obstruction index; BOON = BOO number; BSA = body surface area; BWT = bladder wall thickness; CART = classiﬁcation and regression
tree; DWT = detrusor wall thickness; DAMPF = detrusor-adjusted mean PURR factor; ICS = International Continence Society; LPURR = linear passive urethral
resistance relation; MLL = middle lobe length; NRE = nonrandomised experimental; NIRS = near-infrared spectroscopy; NR = not reported; NPV = negative
predictive value; PCR = penile compression ratio; PCT = penile cuff test; PdetQmax = detrusor pressure at Qmax; Pext max = maximum external pressure;
PPV = positive predictive value; Pts = patients; Qmax = maximum ﬂow; RI = resistive index; RS = retrospective; UEBW = ultrasound-estimated bladder weight;
URA = urethral resistance algorithm; VPG = voiding proﬁlometry gradient across the bladder neck and prostatic urethra in the absence of distal obstruction;
VR = velocity ratio.
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Fig. 2 – Risk of bias assessment for studies included in the systematic
review. The reference numbers for the studies are as in Table 1.
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pool the results of these studies.
3.4.1.2. Uroflowmetry. Uroflowmetry was assessed in
2580 patients across 16 studies. Thirteen studies used a
cutoff value of 10 ml/s to diagnose BOO and reported
median sensitivity of 68.3%, specificity of 70.5%, a PPV of
74.3% and NPV of 68% [7,12,13,15,16,18,20,21,26,30,33,34,
38,40,41]. However, studies varied considerably in their
choice of defining variable and cutoff values. The range of
sensitivity and specificity values across studies was so wide
that no conclusions can be drawn. As would be expected,
lowering the cutoff value for maximum flow (Qmax) seemed
to increase sensitivity at the expense of specificity, and vice
versa. Baseline symptom severity is also a significant
confounder that we are unable to control for with the
available data. Overall, the diagnostic accuracy of uro-
flowmetry in diagnosing BOO appears to be relatively
limited compared to the other index tests.
3.4.1.3. DWT/BWT. DWT was studied in 848 patients across
eight studies [6,8,16,17,24,31,33,34], five of which used a
cutoff of 2 mm to define BOO, with high median sensitivity
of 82.7%, specificity of 92.6%, a PPV of 90.5%, and NPV of
85%. Furthermore, a well-conducted exploratory study
reported a cutoff value of 2.9 mm as having the best
diagnostic value, with specificity of 100%. AlteredDWT and
BWT may have a multifactorial basis, and further assess-
ments in well-designed statistically powered trials are
needed to assess wider application in clinical service
delivery.
3.4.1.4. UEBW. UEBW was only assessed in two studies, both
utilising different threshold values to define BOO, and both
finding a wide variation in diagnostic accuracy
[19,25]. Therefore, little inference can be made from the
available data on bladder weight.
3.4.1.5. External condommethod. The external condom catheter
method was assessed in a single study, which reported that
up to 73% of patients could be correctly diagnosed with this
technique [37]. However, from the limited data available it
appears that test failure for various reasons is a limiting
factor.
3.4.1.6. IPP. IPP was studied in a total of 1013 patients across
ten studies [6,8,9,13,15,17,23,28,36,39]. Five studies used a
cutoff of 10 mm to define BOO, and overall reported similar
diagnostic accuracy to uroflowmetry alone, with median
sensitivity of 67.8% and specificity of 74.8%, a PPV of 73.8%
and NPV of 69.3%. However, threshold values varied,
making interpretation difficult.
3.4.1.7. Doppler ultrasound. Two studies evaluated the role of
Doppler ultrasound, one of which assessed detrusor blood
flow and the other assessed urinary flow velocity
[10,35]. Owing to small patient numbers, the results on
Doppler ultrasound are difficult to interpret with any degree
of certainty.
Table 2 – Summary of results for all the index tests


















Bianchi [11] Grifﬁths nomogram BOOI >40 61.5 NR 44 100 63 67.7 100
Grifﬁths [18] Grifﬁths nomogram BOOI >40 NR NR 39 64 81 68 78
Kazemeyni [22] Grifﬁths nomogram BOOI>40 66.5 NR 35 88.89 75.7 66.7 93
Harding [20] PCR index 160% BOOI >40 63 (20–88) NR 28 78 84 69 NR
Matulewicz [32] Modiﬁed ICS nomogram NR NR 16 (6–30) NR 75 66 92 NR
Salinas [42] Nomogram described BOOI >40 54.1 NR 28 100 55.6 71.4 100
Sullivan [44] PCR 100% VPG >5 cm H2O NR NR 48 90.7 70.2 73.6 89.2
Uroﬂowmetry
Aganovic [7] 10 ml/s LPURR >2 64.68 14.48 63 63 88 94 42
LPURR >3 72 69 69 72
LPURR >2 +
URA >29
72 92 94 68
Qmax <15 +
PdetQmax >50
67 45 50 63
Botkor-Rasmussen [12] 10 ml/s BOOI >40 66 (51–85) a DAN-PSS 4 52 33 100 100 58
Chia [13] 10ml/s BOOI >40 64.6 (50–94) 20.3 63 90 48 74 75
Dicuio [15] 10 ml/s DAMPF score 67.9 (47–86) 22.4 (6–35) 64 NR NR 100 NR
El Saied [16] 10 ml/s BOOI >40 61.7 (53–76) 13.4 (4–22) 46 100 37 57.5 100
Grifﬁths [18] 10 ml/s BOOI >40 NR NR 39 59 89 77 77
Harding [20] 10 ml/s BOOI >40 63 (20–88) NR 28 81 64 51
Hirayama [21] 10 ml/s BOOI >40 67.7 (50–83) 17.1 (9–33) 60 NR NR 65 NR
Ku [26] 10 ml/s BOOI >40 68 (44–89) a 18.1 (no BOO) 27 57.9 65.8 38.4 81
12 ml/s 19.7 (BOO) 77.2 54.2 38.3 86.6
15 ml/s 94.7 27.7 32.5 93.5
Madersbacher [30] 5 ml/s LPURR >2 66.5 (53–81) 16 53 16 96 85.1 46.9
Oelke [34] 15 ml/s CHESS 63 (42–82) 14.4 (2–29) 47 100 25 55 100
Oelke [33] 15 ml/s BOOI >40 62 (40–89) a 15 (2–30) a 47 99 39 59 97
10 ml/s 68 73 69 72
Poulsen [38] 10 ml/s BOOI >40 68 (32-90) 10 (no BOO) e 65 68.7 57.4 74.7 50
15 ml/s 11 (BOO) e 89.9 31.5 70.6 62.9
Reynard [41] 10 ml/s Shafer
nomogram
66.5 (45–88) NR 60 47 70 70 46.5
15 ml/s 82 38 67 57.6
Reynard [40] 10 ml/s 1st void BOOI >40 NR NR 61 71 71 79 61
10 ml/s 4th void 29 96 93 47
DWT
Abdel-Aal [6] 2 mm BOOI >40 58.7 (50–72) 12.45 (6.5–25) 30 65.7 76 65.7 76
El Saied [16] 2 mm BOOI >40 61.7 (53–76) 13.4 (4–22) 46 82.7 92.6 90.5 86.2
Franco [17] 6 mm BOOI >40 67 (48–80) 15 (9–25) 76 73 82 90 50
Kessler [24] 1.5 mm BOOI >40 67 (59–77) a 17 (no BOO) a 60 100 15 64 100
2 mm 22 (BOO) a 92 68 81 85
2.5 mm 69 88 89 65
2.9 mm 43 100 100 54
Oelke [34] 2 mm CHESS 63 (42–82) 14.4 (2–29) 47 63.6 97.3 95.5 75
Oelke [33] 2 mm BOOI >40 62 (40–89) a 15 (2–30) a 47 83 95 94 86
BWT
Aganovic [8] 5 mm BOOI >40 65.4 (48–82) 18.2 (6–31) 49 64.5 59.2 NR NR
Manieri [31] 5 mm URA >29 64.5 (34–88) 14.91 (0–29) 57 55.4 91 87.9 63.4
UEBW
Han [19] b 27.86 g BOOI >40 63.5 19.9 26 61.9 59.8 33.8 82.6
Kojima [25] 35 g BOOI >40 71 (45–89) NR 52 85.3 87.1 87.9 84.4
ECC




Aganovic [8] 10 mm BOOI >40 65.4 (48–82) 18.2 (6–31) 49 59.6 81.4 73.8 69.6
Chia [13] 10 mm BOOI >40 64.6 (50–94) 20.3 63 76 92 94 69
Dicuio [15] 10 mm DAMPF score 67.9 (47–86) 22.4 (6–35) 64 NR NR 100 NR
Lim [28] 10 mm BOOI >40 66 (52–88) a 12 (1–32) a 49 46 65 72 46
Reis [39] 10 mm BOOI >40 64 (56–73) 13 (6–20) 48 80 68.2 69.6 78.9
5 mm BOOI >40 95 50 63.3 91.7
Abdel-Aal [6] 8 mm BOOI >40 58.65 (50–72) 12.45 (6.5–25) 30 80 80 73.7 85.1
Aganovic [9] 12 mm BOOI >40 65.3 (48–80) 18.2 (6–31) NR 59.6 81.3 73.8 69.6
Franco [17] 12 mm BOOI >40 67 (48–80) 15 (9–25) 76 65 77 88 47
Keqin [23] 8.5 mm BOOI >40 71 (55–84) 16.8 (G1–2 IPP) NR 75 82.6 NR NR
18.6 (G3 IPP)
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Pascual [36] 10.5 mm BOOI >40 61.6 (BOO) 14.7 (BOO) 54 90.5 72.2 76 85
64.7 (no BOO) 13.7 (no BOO)
Doppler ultrasound
Belenky [10] RI T >0.05 BOOI >40 65.6 (46–76) NR 75 NR NR 95 57
Ozawa [35] VR >1.6 BOOI >40 NR NR 60 NR NR 100 NR
Prostate volume
El Saied [16] 25 ml BOOI >40 61.7 (53–76) 13.4 (4–22) 46 87 29.6 51.3 72.7
Franco [17] 38 ml BOOI >40 67 (48–80) 16 (9–25) 76 72 61 84 44
Lim [28] 40 ml BOOI >40 66 (52–88) a 12 (1–32) a 49 51 38 65 42
Watanabe [45] d 30 ml and H:W = 0.8 LPURR 3 66.4 (49–84) NR 47 42 100 NR NR
Prostate height
Franco [17] 40 mm BOOI >40 67 (48–80) 16 (9–25) 76 68 54 82 48
NIRS
MacNab [29] NIRS algorithm Not deﬁned 67.3 (50–91) (BOO) 20.2 (no BOO) 49 85.71 88.89 88.89 85.71
56.8 (40–77) (no BOO) 19.6 (BOO)
Yurt [46] NIRS algorithm BOOI >40 58.8 17.8 55 86 87.5 89.2 84
Zhang [47] NIRS algorithm BOOI >40 68.5 (56–85) NR 72 68.3 62.5 82.7 42.9
Chung [14] DP on free ﬂow BOOI >40 67 19 79 34.6 42.9 69.2 15
DP on pressure-ﬂow study BOOI >40 NR NR 79 61.1 40 78.6 22.2
Stothers [43] CART model BOOI >40 62 (49–91) 19 (12–34) 47 100 87.5 93.8 100
BOOI = bladder outﬂow obstruction index; BOOP = BOO prevalence; BWT = bladder wall thickness; CART = classiﬁcation and regression tree; DP = downward
pattern; DWT = detrusor wall thickness; DAMPF = detrusor-adjusted mean PURR factor; ECC = external condom catheter; G1–2 = grade 1–2; G3 = grade 3;
IPP = intravesical prostatic protrusion; IPSS = International Prostate Symptom Score; LPURR = linear passive urethral resistance relation; NIRS = near-infrared
spectroscopy; NR = not reported; NPV = negative predictive value; PCR = penile compression ratio; PPV = positive predictive value; RI = resistive index;
SPY = speciﬁcity; SSY = sensitivity; UEBW = ultrasound-estimated bladder weight; URA = urethral resistance algorithm; VPG = voiding proﬁlometry gradient
across the bladder neck and prostatic urethra in the absence of distal obstruction; VR = velocity ratio.
a Median.
b Corrected UEBW (UEBW/body surface area).
c Results are based on the 46 out of 75 patients (61.3%) who were able to successfully perform the noninvasive test.
d Prostate volume and height:weight (H:W) ratio.
e Danish Prostatic Symptom Score.
E U RO P E AN URO LOGY 7 1 ( 2 0 1 7 ) 3 9 1 – 4 0 23983.4.1.8. Prostate volume and height. Four studies assessed
prostate volume or height using various threshold values;
all of them reported low diagnostic accuracy [16,17,28,45].
3.4.1.9. NIRS. NIRSwas assessed in five studies, three ofwhich
used the NIRS algorithm to define BOO [14,29,43,
46,47]. Overall, diagnostic accuracy was relatively high,
with median sensitivity of 85.7% and specificity of 87.5%.
The one study using a mathematical modelling and
regression tree algorithm showed the highest diagnostic
accuracy [43].Table 3 – Summary of results for each type of index test (grouped)
Test Studies Pts Sensitivity Spec
(n) (n) Median (IQR) Range Median (IQR
Penile cuff test 7 546 88.89 (76.5–95.3) 64–100 70.2 (64.5–78
Uroﬂowmetry 16 2580 72 (58.4–89.9) 16–100 64 (38.5–81)
DWT 8 848 69 (64–82.8) 43–100 88 (72–93.8)
Bladder weight 2 258 73.6 61.9–85.3 73.45
ECC 1 56 90.9 92.3
IPP 10 1013 75.5 (60.9–80) 46–95 78.5 (69.2–81
Doppler US 2 51 No data No data No data
Prostate volume 3 245 72 (61.5–79.5) 51–87 38 (33.8–49.5
NIRS 5 282 85.71 (68.3–86) 61.1–100 87.5 (62.5–87
Pts = patients; IQR = interquartile range; DWT = detrusor wall thickness; E
US = ultrasound; NIRS = near-infrared spectroscopy.3.4.2. Results for secondary outcomes
Secondary outcomes were not addressed owing to a lack of
data suitable for a critical analysis.
3.5. Discussion
3.5.1. Principal findings
A total of 42 studies recruiting 4444 patients were eligible
for inclusion in this SR, which assessed the diagnostic
accuracy of nine noninvasive tests. There were significant
variations among studies investigating the same test, iniﬁcity Positive predictive value Negative predictive value
) Range Median (IQR) Range Median (IQR) Range
.3) 55.6–84 69 (67.9–72.5) 66.7–92 93 (89.2–100) 78–100
25–100 70 (57.5–79) 32.5–100 70 (57.7–85.2) 46.5–100
15–100 89.5 (82.7–93.1) 64–100 75.5 (63.8–85.7) 50–100
59.8– 87.1 60.85 33.8–87.9 83.5 82.6–84.4
96.7 80
.3) 50–92 73.8 (72.4–85) 69.6–100 69.6 (69–85) 46–85.1
No data 97.5 (96.2–98.7) 95–100 57 No data
) 29.6–61 65 (58.1–74.5) 51.3–84 44 (43–58.3) 42–72.7
.5) 40–87.5 88.89 (82.7–89.2) 78.6–93.8 84 (42.9–85.71) 22.2–100
CC = external condom catheter; IPP = intravesical prostatic protrusion;
Table 4 – Summary of results for each type of index test using the most commonly used threshold values relevant to each test (grouped)
Test Threshold
value
Studies Pts Sensitivity Speciﬁcity Positive predictive value Negative predictive value
(n) (n) Median (IQR) Range Median (IQR) Range Median (IQR) Range Median (IQR) Range
PCT Grifﬁths NG 3 243 88.9 (76.4–94.4) 64–100 75.7 (69.3–78.3) 63–81 67.7 (67.2–67.9) 66.7–68 93 (85.5–96.5) 78–100
UF 10ml/s 13 2257 68.3 (55.1–74.2) 29–100 70.5 (62.3–89.7) 37–100 74.3 (66–89.5) 38.4–100 68 (54–76) 46.5–100
DWT 2mm 5 467 82.7 (65.7–83) 63.6–92 92.6 (76–95) 68–97.3 90.5 (81–94) 65.7–95.5 85 (76–86) 75–86.2
IPP 10mm 5 473 67.8 (56.2–77) 46–80 74.8 (67.4–84) 65–92 73.8 (72–94) 69.6–94 69.3 (63.2–71.9) 46–78.9
NIRS NIRS algorithm 3 195 85.71 (77–85.8) 68.3–86 87.5 (75–88.1) 62.5–88.9 88.89 (85.7–89) 82.7–89.2 84 (63.4–84.8) 42.9–85.71
Pts = patients; IQR = interquartile range; PCT = penile cuff test; NG = nomogram; UF = uroﬂowmetry; DWT = detrusor wall thickness; ECC = external condom
catheter; IPP = intravesical prostatic protrusion; NIRS = near-infrared spectroscopy.
E U RO P E AN URO LOG Y 7 1 ( 2 0 1 7 ) 3 9 1 – 4 0 2 399terms of both the threshold value used to define BOO on the
noninvasive test and the nomograms used to diagnose BOO
on invasive urodynamics. Studies reporting on the most
commonly used thresholds to define BOO — PCT using the
Griffiths nomogram, DWT >2 mm, and the NIRS algorithm
— had the highest median sensitivity, ranging from 82% to
85.7%. These three tests also had the highestmedianNPVs of
84–89%. The highest median PPVs were reported for DWT
>2 mm and the NIRS algorithm, at 90%. The diagnostic
accuracy for IPP >10 mm was similar to that for Qmax
<10 ml/s on free-flow rate testing. The studies on IPP also
appeared to show that specificity increased with the IPSS
score, a confounder that would be controlled for in a good
prospective trial. The diagnostic ability of the external
condom catheter seems promising in the only study
included, but these data require further validation in future
studies.
Although the overall RoB was low across many domains
for the majority of studies, in many studies, the index test
and reference standard were performed unblinded, and in
some studies the two tests were performed simultaneously
by the same investigator who also analysed the results
obtained. This could have potentially biased the interpreta-
tion of the findings and final conclusions reached.
3.5.2. Implications for clinical practice
Pressure-flow studies for evaluation of men with LUTS are
often not performed for practical reasons. Several noninva-
sive techniques have therefore been developed and appear
promising in the assessment of men with LUTS. From the
evidence reviewed in this paper, PCT, DWT, UEBW, andNIRS
show the greatest diagnostic accuracy, although further
validation in studies with more stringent methodological
standards are required before they can replace invasive
urodynamics. Furthermore, a number of factors need to be
considered when discussing the generalisability and deliv-
ery costs of these tests. PCT may cause discomfort or
urethral bleeding, although this has been reported in only
2% of patients, and it has been reported that technical
difficulties result in exclusion rates of 23–46% [18,48]. Simi-
larly, the external condom method may also cause
discomfort and results may be affected by low flow rates,
low voided volumes, and abdominal straining [37]. Mea-
surement of DWT and UEBW require specific training and
there is a risk of observer error, and NIRS requires
specialised equipment. Doppler ultrasound urodynamicssuffers from the same limitations of observer error and
requires specialised equipment. It is clear that these
techniques, either alone or in combination, may be used
to aid in decision-making and counselling when evaluating
men with LUTS in daily clinical practice, especially if
invasive urodynamics are unavailable or contraindicated.
However, the quality of the current data is insufficient to
recommend the routine use of any noninvasive test over
pressure-flow studies in diagnosing BOO in men with LUTS.
3.5.3. How the review compares to previous reviews/guidelines
A number of studies reviewing the evidence for various
noninvasive urodynamic tests have been published in
recent years [49–56]. All reviews have reported similar
findings to the present review: some noninvasive tests
appear promising, especially in combination, but further
investigation is required before they can replace invasive
urodynamics. Importantly, however, the methodology in
these reviews differs significantly from the present SR.
Primarily, this SR is based on strict inclusion and exclusion
criteria with input from a multidisciplinary expert panel to
inform the review question. The robust methods used to
synthesise the evidence and analyse the data are the
principal strengths of this study and therefore provide a
more accurate evaluation of the available evidence com-
pared to the other reviews.
3.5.4. Future research
This review has demonstrated that several noninvasive
tests seem promising in assessing men with BOO. However,
we have highlighted the limitations of the current evidence
base in terms of heterogeneity of definitions and threshold
values used. Therefore, larger studies with more stringent
methodological standards are required to better assess their
role in the evaluation of men with LUTS. The limitations of
existing individual tests have led many investigators to
assess the role of a combination of tests in improving
diagnostic accuracy for BOO. Although not covered in this
SR, the role of combining tests is a promising area that
requires further assessment.
3.5.5. Strengths and limitations
The strengths of this review are the systematic, transparent,
and effective approach taken to examine the evidence base,
including the use of Cochrane review methodology, RoB
assessment using QUADAS-2, and adherence to PRISMA and
E U RO P E AN URO LOGY 7 1 ( 2 0 1 7 ) 3 9 1 – 4 0 2400STARD guidelines. The clinical question was prioritised by a
multidisciplinary panel of clinical experts, methodologists,
and patient representatives (EAU Non-neurogenic Male
LUTS Guideline Panel), and theworkwas undertaken as part
of the panel’s clinical practice guideline update for 2016. In
addition, the review elements, including participant char-
acteristics, index and reference tests, definitions and
thresholds, were developed a priori in conjunction with
the panel. The search strategy was complemented by
additional sources of potentially important articles, includ-
ing reference lists for the studies included, and studies
identified by the expert panel. This approach ensured a
comprehensive review of the literature while maintaining
methodological rigour and enabled the authors to put into
clinical context the relevance and implications of the review
findings. Moreover, the vast majority of studies were
prospective in nature, with well-defined index and refer-
ence tests, and the overall RoB was generally low across
studies. The primary limitation was the large heterogeneity
among studies with regard to definitions of index tests and
reference standards. Furthermore, owing to a lack of data
wewere unable to perform any subgroup analyses. Another
limitation is the basic assumption that invasive urody-
namics is a definitive diagnostic investigation for BOO
inmen. It is known that results of invasive urodynamics and
the nomograms based on pressure-flow studies can
have significant inter- and intra-investigator variability,
as well as test-retest variation [57,58]. However, in the
absence of a more accurate gold standard, all studies on
these diagnostic tests will continue to be compared to
invasive urodynamics.
4. Conclusions
We systematically reviewed studies assessing the diagnostic
accuracy of noninvasive tests in diagnosing BOO inmenwith
LUTS using effective methods for evidence acquisition and
synthesis, with input from a multidisciplinary expert panel
to inform the review question and review elements. The
findings and clinical relevance were interpreted using an
appropriate clinical context provided by the expert panel.
Overall, a number of noninvasive tests appear promising,
with low RoB across most domains for the great majority of
studies. Limitations of the current evidence base include
heterogeneity of definitions and thresholds for index tests
and reference standards, and therefore this reviewhighlights
the need for larger prospective studies with better method-
ological quality. In spite of these limitations, the findings
from this review can help to provide clinical guidance on
the accuracy of these tests in daily practice. Therefore, while
several tests have shown promising results for noninvasive
assessment of BOO, a pressure-flow study remains the gold
standard test in determining BOO.
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